The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases.
Source link
Tags: acquisitions, Acquisitions/Mergers, Acquisitions/Mergers/Shareholdings, BIIB, Biogen, Biopharmaceuticals, Biotechnology Services, C&E Executive News Filter, C&E Industry News Filter, Content Types, corporate, Corporate Actions, Corporate/Industrial News, Earnings, Factiva Filters, Financial Performance, government policy, healthcare, Healthcare/Life Sciences, industrial news, labor, Labor/Personnel, lay-offs, Lay-offs/Redundancies, life sciences, Management, Management Moves, mergers, new products, New Products/Services, Ownership Changes, personnel, Pharmaceuticals, product, Product/Service Approvals, products, Products/Services, Reata Pharmaceuticals, redundancies, regulation, Regulation/Government Policy, RETA, Sales Figures, Senior Level Management, service approvals, services, shareholdings, SYND, WSJ-PRO-WSJ.com, wsjhealth
